SwePub - search: id:"swepub:oai:gup.ub.gu.se/28...

Enumeration	Reference	Cover	Find
1.	Wilhelmson, Mari, et al. (author) Hospitalizations in Long-term Survivors of Childhood AML Treated with Allogeneic HSCT - an Adult Life after Childhood Cancer in Scandinavia (ALiCCS) Study 2019 In: 38th NOPHO Annual meeting. Aalborg, Denmark 3-7 May. Conference paper (other academic/artistic)abstract Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is effective in treating childhood acute myeloid leukemia (AML) but the long-term disease burden may be increased. In a population-based study, the standardized hospitalization rates ratios (SHRR) and absolute excess risks for disease specific hospitalizations were evaluated in 5-year survivors of AML treated at 0-17 years of age according to the NOPHO-AML protocols in four Nordic countries during 1984-2005. In total, 229 eligible AML survivors were identified in the NOPHO-AML database and the treatment data of 196 survivors could be linked to 5-year follow-up data in national hospital registries. After a median follow-up time of 12 (range 5–28) years, 35 out of the 97 survivors treated with allo-HSCT had been hospitalized (SHRR 2.8 (95% CI 2.0– 4.0) with increased risk for hospitalizations due to cardiovascular 8.7 (3.9–19), endocrine 12 (6.7–22), pulmonary 3.0 (1.8–5.2), gastrointestinal 4.0 (2.4–6.7), infectious 3.1 (1.3–7.6), neurological 4.4 (2.1–9.2) and uro-genital system conditions 2.9 (1.3–6.4). In comparison, after a median follow-up time of 11 (range 5–28) years, 21 out of the 99 survivors treated with chemotherapy alone had been hospitalized; SHRR 1.4 (0.9–2.1). Our results indicate that hospitalization rates are significantly increased in long-term survivors of childhood AML if treated with allo-HSCT but not in survivors treated with chemotherapy only.

Wilhelmson, Mari, et al. (author)
Hospitalizations in Long-term Survivors of Childhood AML Treated with Allogeneic HSCT - an Adult Life after Childhood Cancer in Scandinavia (ALiCCS) Study
2019
In: 38th NOPHO Annual meeting. Aalborg, Denmark 3-7 May.
Conference paper (other academic/artistic)abstract
- Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is effective in treating childhood acute myeloid leukemia (AML) but the long-term disease burden may be increased. In a population-based study, the standardized hospitalization rates ratios (SHRR) and absolute excess risks for disease specific hospitalizations were evaluated in 5-year survivors of AML treated at 0-17 years of age according to the NOPHO-AML protocols in four Nordic countries during 1984-2005. In total, 229 eligible AML survivors were identified in the NOPHO-AML database and the treatment data of 196 survivors could be linked to 5-year follow-up data in national hospital registries. After a median follow-up time of 12 (range 5–28) years, 35 out of the 97 survivors treated with allo-HSCT had been hospitalized (SHRR 2.8 (95% CI 2.0– 4.0) with increased risk for hospitalizations due to cardiovascular 8.7 (3.9–19), endocrine 12 (6.7–22), pulmonary 3.0 (1.8–5.2), gastrointestinal 4.0 (2.4–6.7), infectious 3.1 (1.3–7.6), neurological 4.4 (2.1–9.2) and uro-genital system conditions 2.9 (1.3–6.4). In comparison, after a median follow-up time of 11 (range 5–28) years, 21 out of the 99 survivors treated with chemotherapy alone had been hospitalized; SHRR 1.4 (0.9–2.1). Our results indicate that hospitalization rates are significantly increased in long-term survivors of childhood AML if treated with allo-HSCT but not in survivors treated with chemotherapy only.

Träfflista för sökning "id:"swepub:oai:gup.ub.gu.se/287640" "

Refine your search